Bill Gadless: Big Moment for CAR-T
Bill Gadless, Founding Partner at emagine / emagineHealth, shared a post on LinkedIn:
“Big moment for CAR-T.
The ‘in vivo’ version just cleared a major milestone.
Interius BioTherapeutics dosed the first cancer patient with CAR-T cells made inside the body last fall. Now Carl June’s UPenn team has published results in Science showing how targeted nanoparticles can do the same – no external manufacturing.
Why this matters:
- Current CAR-T runs $500K+ per patient
- Weeks to make, only at select centers
- Many patients die waiting
- Manufacturing failures = no treatment at all
June’s method packages RNA into nanoparticles that reprogram T-cells in the patient. In monkeys – cancer cells gone in a day. In mice – tumors undetectable after 3 weeks.
With Interius, EsoBiotec, and UPenn all closing in from different angles, this field isn’t “promising” anymore – it’s maturing.
No cross-country blood shipments. No months-long wait. Just an infusion any cancer center could give. We’ve built Ferraris when patients needed Fords. Now the road’s finally opening.”
More Posts Featuring CAR-T cells.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023